A5102923441- Inflammatory Bowel Disease
- Microscopic Colitis
- Liver Diseases and Immunity
- Immunodeficiency and Autoimmune Disorders
- Eosinophilic Esophagitis
- Biosimilars and Bioanalytical Methods
- Autoimmune and Inflammatory Disorders
- Helicobacter pylori-related gastroenterology studies
- Celiac Disease Research and Management
- Autoimmune and Inflammatory Disorders Research
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Pregnancy and Medication Impact
- Pharmaceutical studies and practices
- Gastrointestinal Bleeding Diagnosis and Treatment
- Gastrointestinal disorders and treatments
- Monoclonal and Polyclonal Antibodies Research
- Adolescent and Pediatric Healthcare
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Gastrointestinal Tumor Research and Treatment
- Mycobacterium research and diagnosis
- Multiple Sclerosis Research Studies
- Sphingolipid Metabolism and Signaling
Atlanta Gastroenterology Associates
2016-2025
Ibero American University
2017
Universitair Ziekenhuis Leuven
2005-2012
Prometheus (United States)
2010
Mount Sinai Medical Center
2007-2008
Medical College of Wisconsin
2008
Cleveland Clinic
2006-2007
Hôpital Claude Huriez
2006-2007
University of Calgary
2005-2007
Atlanta Diabetes Associates
2006-2007
Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas. It not known whether infliximab
Adalimumab induced clinical remission after four weeks in patients with active Crohn's disease the CLASSIC I trial.To evaluate long term efficacy and safety of adalimumab maintenance therapy a follow-on randomised controlled trial (CLASSIC II).In preceding trial, 299 moderate to severe naive tumour necrosis factor antagonists received induction 40 mg/20 mg, 80 mg/40 or 160 mg/80 placebo, at 0 2. In all, 276 from enrolled II open-label mg (week 4 I) 2; 55 both were re-randomised every other...
Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease.We conducted phase 3, multicenter, randomized, double-blind, placebo-controlled trial ozanimod as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. In 10-week period, cohort 1 were assigned receive oral hydrochloride at dose mg (equivalent 0.92 ozanimod) or placebo once daily double-blind manner, 2 received...
Etrasimod, a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively activates S1P subtypes 1, 4, and 5, with no detectable activity on S1P2,3, is in development for the treatment of immune-mediated diseases, including ulcerative colitis. In these two phase 3 trials, we aimed to evaluate safety efficacy etrasimod adult patients moderately severely active colitis.In independent randomised, multicentre, double-blind, placebo-controlled, ELEVATE UC 52 12, adults...
Aliment Pharmacol Ther 2010; 32: 1228–1239 Summary Background Adalimumab induces and maintains remission in adults with Crohn’s disease. Aim To evaluate safety, fistula healing, quality of life work productivity adalimumab‐treated patients who failed infliximab, including primary nonresponders. Methods After a ≥8‐week infliximab washout, moderate‐to‐severe disease received open‐label adalimumab as induction (160/80 mg at weeks 0/2) maintenance (40 every other week) therapies. At/after 8...
The safety and efficacy of adalimumab for patients with moderately to severely active ulcerative colitis (UC) has been reported up week 52 from the placebo-controlled trials ULTRA (Ulcerative Colitis Long-Term Remission Maintenance Adalimumab) 1 2. Up 4 years data adalimumab-treated 1, 2, open-label extension 3 are presented.Remission per partial Mayo score, remission Inflammatory Bowel Disease Questionnaire (IBDQ) mucosal healing rates were assessed in adalimumab-randomized 2 208....
Variation in adherence to management guidelines for inflammatory bowel disease (IBD) suggests variable quality of care. Quality indicators (QIs) can be developed measure the structure, processes, and outcomes health care delivery. The RAND/UCLA appropriateness method was used develop a set process outcome QIs define IBD.Guidelines position papers IBD published from 2006 2011 were reviewed potential QIs, which rated by multidisciplinary panel. Potential discussed at 3 moderated in-person...
Abstract Background and Aims This analysis examined the long-term safety efficacy of ozanimod in patients with moderately to severely active ulcerative colitis [UC] ≥ 4 years follow-up phase 2 TOUCHSTONE open-label extension [OLE]. Methods Patients receiving placebo or HCl 0.5 mg 1 during double-blind period could enter OLE [ozanimod daily]. Partial Mayo score [pMS] clinical response remission were assessed through week 200 summarized descriptively using observed cases [OC] non-responder...
BACKGROUND & AIMS Although biologics have revolutionized treatment of Crohn's disease (CD), an efficacy ceiling has been reached. Combining biologic therapies may improve remission rates. METHODS EXPLORER, a phase 4, single-arm, open-label study, evaluated triple combination therapy with vedolizumab (300 mg on day 1, weeks 2 and 6, then every 8 weeks), adalimumab (160 2, 80 at week 40 methotrexate (15 weekly) in biologic-naïve patients newly diagnosed, moderate- to high-risk CD. Endoscopic...